396 related articles for article (PubMed ID: 36509071)
21. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
[TBL] [Abstract][Full Text] [Related]
22. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab.
Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N
BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948
[TBL] [Abstract][Full Text] [Related]
23. Isolated neutropenia as a rare but serious adverse event secondary to immune checkpoint inhibition.
Naqash AR; Appah E; Yang LV; Muzaffar M; Marie MA; Mccallen JD; Macherla S; Liles D; Walker PR
J Immunother Cancer; 2019 Jul; 7(1):169. PubMed ID: 31277704
[TBL] [Abstract][Full Text] [Related]
24. Palliative care physicians' recognition of patients after immune checkpoint inhibitors and immune-related adverse events.
Usui Y; Miura T; Kawaguchi T; Kosugi K; Uehara Y; Kato M; Kosugi T; Sone M; Nakamura N; Mizushima A; Miyashita M; Morita T; Yamaguchi T; Matsumoto Y; Satomi E
Support Care Cancer; 2022 Jan; 30(1):775-784. PubMed ID: 34383113
[TBL] [Abstract][Full Text] [Related]
25. Management of immune-related adverse events resulting from immune checkpoint blockade.
Baroudjian B; Arangalage D; Cuzzubbo S; Hervier B; Lebbé C; Lorillon G; Tazi A; Zalcman G; Bouattour M; Lioté F; Gautier JF; Brosseau S; Lourenco N; Delyon J;
Expert Rev Anticancer Ther; 2019 Mar; 19(3):209-222. PubMed ID: 30572735
[TBL] [Abstract][Full Text] [Related]
26. Comparative severe dermatologic toxicities of immune checkpoint inhibitors in malignant melanoma: A systematic review and network meta-analysis.
Mao YT; Wang Y; Chen XX; Liu CJ; Bao Q
J Cosmet Dermatol; 2024 Apr; 23(4):1165-1177. PubMed ID: 38013634
[TBL] [Abstract][Full Text] [Related]
27. A Retrospective Cohort Study of Multiple Immune-Related Adverse Events and Clinical Outcomes Among Patients With Cancer Receiving Immune Checkpoint Inhibitors.
Hata H; Matsumura C; Chisaki Y; Nishioka K; Tokuda M; Miyagi K; Suizu T; Yano Y
Cancer Control; 2022; 29():10732748221130576. PubMed ID: 36254804
[TBL] [Abstract][Full Text] [Related]
28. Multisystem Immune-Related Adverse Events from Dual-Agent Immunotherapy Use.
Li Y; Pond G; McWhirter E
Curr Oncol; 2024 Jan; 31(1):425-435. PubMed ID: 38248113
[TBL] [Abstract][Full Text] [Related]
29. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of immune checkpoint inhibitors in patients with anorectal melanoma in association with immune-related adverse events: a case series.
Yokoyama R; Sato Y; Nakamura F; Kagemoto K; Mitsui Y; Okamoto K; Kawano Y; Sogabe M; Miyamoto H; Takayama T
Clin J Gastroenterol; 2023 Dec; 16(6):842-847. PubMed ID: 37632658
[TBL] [Abstract][Full Text] [Related]
31. Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer.
Berti A; Bortolotti R; Dipasquale M; Kinspergher S; Prokop L; Grandi G; Inchiostro S; Paolazzi G; Caffo O; Veccia A
Crit Rev Oncol Hematol; 2021 Jun; 162():103351. PubMed ID: 33989769
[TBL] [Abstract][Full Text] [Related]
32. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
33. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer: A Network Meta-Analysis of Randomized Clinical Trials.
Zhang W; Gu J; Bian C; Huang G
Front Pharmacol; 2021; 12():686876. PubMed ID: 34759817
[No Abstract] [Full Text] [Related]
34. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint inhibitor-induced diabetes mellitus with nivolumab.
Zand Irani A; Gibbons H; Teh WX
BMJ Case Rep; 2023 Apr; 16(4):. PubMed ID: 37011994
[TBL] [Abstract][Full Text] [Related]
36. Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors.
Martini DJ; Goyal S; Liu Y; Evans ST; Olsen TA; Case K; Magod BL; Brown JT; Yantorni L; Russler GA; Caulfield S; Goldman JM; Nazha B; Harris WB; Kissick HT; Master VA; Kucuk O; Carthon BC; Bilen MA
Oncologist; 2021 Oct; 26(10):e1742-e1750. PubMed ID: 34156726
[TBL] [Abstract][Full Text] [Related]
37. Meta-analysis of immune-related adverse events of immune checkpoint inhibitor therapy in cancer patients.
Song P; Zhang D; Cui X; Zhang L
Thorac Cancer; 2020 Sep; 11(9):2406-2430. PubMed ID: 32643323
[TBL] [Abstract][Full Text] [Related]
38. Role-Specific Curricular Needs for Identification and Management of Immune-Related Adverse Events.
Wesevich A; He G; Tomczyk G; Reid P
J Cancer Educ; 2023 Oct; 38(5):1486-1492. PubMed ID: 37022615
[TBL] [Abstract][Full Text] [Related]
39. Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis.
Larkin J; Chmielowski B; Lao CD; Hodi FS; Sharfman W; Weber J; Suijkerbuijk KPM; Azevedo S; Li H; Reshef D; Avila A; Reardon DA
Oncologist; 2017 Jun; 22(6):709-718. PubMed ID: 28495807
[TBL] [Abstract][Full Text] [Related]
40. Prognosis of Immune-related Adverse Events in Patients With Advanced Gastric Cancer Treated With Nivolumab or Pembrolizumab: A Multicenter Retrospective Analysis.
Ando T; Ueda A; Ogawa K; Motoo I; Kajiura S; Nakajima T; Hirano K; Okumura T; Tsukada K; Hara T; Suzuki N; Nakada N; Horikawa N; Fujii T; Yasuda I
In Vivo; 2021; 35(1):475-482. PubMed ID: 33402499
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]